Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 15, Issue 2, 2014, Pages 177-189

  Gu, Chunyan ^a   Zhou, Guangyu ^a   Noble, Nancy A ^a   Border, Wayne A ^a   Cheung, Alfred K ^a   Huang, Yufeng ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

albuminuria; Angiotensin II; ARB; podocyte; renal fibrosis

Indexed keywords

ANGIOTENSIN II; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DRINKING WATER; FIBRONECTIN; MESSENGER RNA; MONOCLONAL ANTIBODY; NEPHRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PODOCIN; THY 1.1 ANTIBODY; THY 1.1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; MEMBRANE PROTEIN; SIGNAL PEPTIDE; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DAMAGE; CELL EXPANSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EXTRACELLULAR MATRIX; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; GLOMERULUS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPTIMAL DRUG DOSE; PODOCYTE; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; RISK REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; KIDNEY; KIDNEY FUNCTION TEST; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; GLOMERULONEPHRITIS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MEMBRANE PROTEINS; PODOCYTES; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; VALINE;

EID: 84902165229     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312466127     Document Type: Article

References (42)

1. Gaedeke J, Peters H, Noble NA, et al. Angiotensin II, TGF-ß and renal fibrosis. Contrib Nephrol. 2001 ; 135: 153-160
2. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007 ; 18: 1889-1898
3. Fujihara CK, Velho M, Malheiros DM, et al. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int. 2005 ; 67: 1913-1924
4. Teles F, Machado FG, Ventura BH, et al. Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int. 2009 ; 75: 72-79
5. Tominaga N, Robert A, Izuhara Y, et al. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model. Nephrology. 2009 ; 14: 581-587
6. Weinberg AJ, Zappe DH, Ashton M, et al. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: A pilot study. Am J Nephrol. 2004 ; 24: 340-345
7. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial. Lancet. 2009 ; 374: 1840-1848
8. Woo KT, Chan CM, Tan HK, et al. Beneficial effects of high-dose losartan in IgA nephritis. Clin Nephrol. 2009 ; 71: 617-624
9. Weir MR, Hollenberg NK, Zappe DH, et al. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J Hypertens. 2010 ; 28: 186-193
10. Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007 ; 25: 1921-1926
11. Okumi M, Kawada N, Ichimaru N, et al. Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients. Clin Exp Nephrol. 2011 ; 15: 907-915
12. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. 1998 ; 54: 1570-1580
13. Bagchus WM, Hoedemaeker PJ, et al. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest. 1986 ; 55: 680-687
14. Peters H, Border WA, Noble NA. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. Kidney Int. 2000 ; 57: 1493-1501
15. Yu L, Border WA, Anderson I, et al. Combining TGF-ß inhibition and angiotensin II blockade results in enhanced anti-fibrotic effect. Kidney Int. 2004 ; 66: 1774-1784
16. Huang Y, Border WA, Yu L, et al. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol. 2008 ; 19: 329-338
17. Shankland SJ. The podocyte's response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int. 2006 ; 69: 2131-2147
18. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 2008 ; 4: 39-45
19. Yu D, Petermann A, Kunter U, et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005 ; 16: 1733-1741
20. Han GD, Koike H, Nakatsue T, et al. IFN-inducible protein-10 has a differential role in podocyte during Thy 1.1 glomerulonephritis. J Am Soc Nephrol. 2003 ; 14: 3111-3126
21. Morioka Y, Koike H, Ikezumi Y, et al. Podocyte injuries exacerbate mesangial proliferative glomerulonephritis. Kidney Int. 2001 ; 60: 2192-2204
22. Ebrahim H, Evans DJ. Antibody induced injury to podocytes with proteinuria and foot process swelling in a transgenic (T16) mouse. Int J Exp Pathol. 1999 ; 80: 77-86
23. Kawachi H, Miyauchi N, Suzuki K, et al. Role of podocyte slit diaphragm as a filtration barrier. Nephrology. 2006 ; 11: 274-281
24. Sanden SK, Wiggins JE, Goyal M, et al. Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms' tumor-1 protein used as a podocyte nuclear marker. J Am Soc Nephrol. 2003 ; 14: 2484-2493
25. Guo JK, Menke AL, Gubler MC, et al. WT1 is a key regulator of podocyte function: Reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet. 2002 ; 11: 651-659
26. Liu G, Kaw B, Kurfis J, et al. Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J Clin Invest. 2003 ; 112: 209-221
27. Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004 ; 113: 1390-1397
28. Okuda S, Nakamura T, Yamamoto T, et al. Dietary protein restriction rapidly reduces transforming growth factor β1 expression in experimental glomerulonephritis. Proc Natl Acad Sci U S A. 1991 ; 88: 9765-9769
29. Villa L, Boor P, Konieczny A, et al. Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. Nephrol Dial Transplant. 2011 ; 26: 3131-3143
30. Zhang J, Gu C, Noble NA, et al. Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis. Am J Physiol Renal Physiol. 2011 ; 301: F723 - F732
31. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol. 1992 ; 140: 95-107
32. Kagami S, Border WA, Miller DE, et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994 ; 93: 2431-2437
33. Kagami S, Kuhara T, Okada K, et al. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int. 1997 ; 51: 664-671
34. Tuncdemir M, Ozturk M. The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy. Acta Histochem. 2011 ; 113: 826-832
35. Mifsud SA, Allen TJ, Bertram JF, et al. Podocyte foot process broadening in experimental diabetic nephropathy: Amelioration with renin-angiotensin blockade. Diabetologia. 2001 ; 44: 878-882
36. Sofue T, Kiyomoto H, Kobori H, et al. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens. 2012 ; 25: 604-611
37. Fukuda A, Wickman LT, Venkatareddy MP, et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int. 2012 ; 81: 40-55
38. Abbas AK, Sharpe AH. T-cell stimulation: An abundance of B7s. Nat Med. 1999 ; 5: 1345-1346
39. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol. 1999 ; 11: 203-210
40. Yadav A, Vallabu S, Arora S, et al. ANG II promotes autophagy in podocytes. Am J Physiol Cell Physiol. 2010 ; 299: C488 - C496
41. Ren Z, Liang W, Chen C, et al. Angiotensin II induces nephrin dephosphorylation and podocyte injury: Role of caveolin-1. Cell Signal. 2012 ; 24: 443-450
42. Hsu HH, Hoffmann S, Endlich N, et al. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med. 2008 ; 86: 1379-1394